Deficient FANCL Predisposes to Endothelial Damage: A New Therapeutic Target for Pulmonary Hypertension
<b>Rationale:</b> Clinical observations have suggested an association between alkylating agent-based chemotherapy and pulmonary arterial hypertension (PAH). The Fanconi anemia (FA) pathway, the principal mechanism for resolving alkylating agent-induced DNA damage, has been implicated in this process. <b>Objectives:</b> To establish the interplay among the FA pathway, DNA damage, and PAH. <b>Methods:</b> A knockout-first mouse model for FA complementation group L (<i>Fancl</i><sup>kf/kf</sup>) and an adenovirus-associated virus 9-mediated <i>Fancl</i> overexpression (AAV-<i>Fancl</i>) model were used. Lung specimens, pulmonary arterial endothelial cells from patients with PAH, and primarily cultured pulmonary microvascular endothelial cells (PMVECs) from wild-type and <i>Fancl</i><sup>kf/kf</sup> mice were analyzed. <b>Measurements and Main Results:</b> Data analysis on lung single-cell RNA-sequencing datasets revealed significant downregulation of <i>FANCL</i> in endothelial cells from patients with idiopathic PAH, a finding consistently validated in both clinical samples (lung specimens and pulmonary arterial endothelial cells) and the monocrotaline-induced PAH rat model. Notably, <i>Fancl</i><sup>kf/kf</sup> mice developed spontaneous PAH and showed heightened susceptibility to alkylating agent (mitomycin C)-induced PAH, characterized by severe DNA damage and apoptosis in PMVECs. These pathological phenotypes were rescued through <i>Fancl</i> gene supplementation via AAV-<i>Fancl</i> or pharmacological intervention with the DNA damage protector amifostine. Mechanistically, transcriptomic profiling combined with functional validation demonstrated a suppressed bone morphogenetic protein signaling coupled with hyperactivated transforming growth factor-β pathways in PMVECs from <i>Fancl</i><sup>kf/kf</sup> mice. Importantly, this imbalance was fully restored in PMVECs from AAV-<i>Fancl</i>-treated mice. <b>Conclusions:</b> Deficient <i>Fancl</i> plays a key role to promote PAH, and targeted rescue of <i>Fancl</i> could be a novel effective strategy for the treatment of PAH.
Authors
- Wenju Lu (ORCID: https://orcid.org/0000-0002-5035-9287)
- Ran Xu (ORCID: https://orcid.org/0000-0002-7051-8564)
- Rong Guo (ORCID: https://orcid.org/0000-0003-2799-3463)
- Haiyang Tang (ORCID: https://orcid.org/0000-0001-9537-2891)
- Shaocong Mo (ORCID: https://orcid.org/0000-0001-8556-1314)
- Kai Yang (ORCID: https://orcid.org/0000-0003-3044-2240)
- Jason X.‐J. Yuan (ORCID: https://orcid.org/0000-0002-0685-4862)
- Yuqi Zhou (ORCID: https://orcid.org/0000-0003-4988-7637)
- Chenting Zhang
- Dongyi Xu (ORCID: https://orcid.org/0000-0001-5711-2618)
- Huazhuo Feng (ORCID: https://orcid.org/0009-0006-5565-2876)
- Zizhou Zhang
- Xiuzhen Bai
- C. Liu (ORCID: https://orcid.org/0000-0003-2205-8425)
- Junqi Zhu (ORCID: https://orcid.org/0000-0002-5247-9805)
- Zifeng Yang
- Changlei Bao (ORCID: https://orcid.org/0000-0002-1773-3986)
- Xiaoqian Shan (ORCID: https://orcid.org/0000-0002-0745-8343)
- Shiyun Liu (ORCID: https://orcid.org/0000-0002-4174-6189)
- Jian Wang (ORCID: https://orcid.org/0000-0002-1278-256X)
- Lei Xu
- Jiang Qian (ORCID: https://orcid.org/0000-0002-0476-3596)
- Haixia Chen (ORCID: https://orcid.org/0000-0001-8561-5351)
- Jiaxuan Lai
- Wei Feng (ORCID: https://orcid.org/0000-0002-4991-3244)
- Haiyun Luo (ORCID: https://orcid.org/0000-0002-3346-7948)
- Yuqin Chen (ORCID: https://orcid.org/0000-0002-7011-7250)
- Xinlin Xu (ORCID: https://orcid.org/0009-0004-7874-359X)
- Yufei Sun
- Xiaoyun Luo
Institutions
- Scripps Research Institute (US)
- Harvard University (US)
- Sun Yat-sen University (CN)
- Peking University (CN)
- Guangzhou Experimental Station (CN)
- First Affiliated Hospital of Guangzhou Medical University (CN)
- Dana-Farber Cancer Institute (US)
- Third Affiliated Hospital of Sun Yat-sen University (CN)
- New York Genome Center (US)
- Guangzhou Medical University Cancer Hospital (CN)
- State Key Laboratory of Respiratory Disease (CN)
- Inner Mongolia Medical University (CN)
- Hubei University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- American Journal of Respiratory and Critical Care Medicine
- Published
- 2025-06-13
- DOI
- https://doi.org/10.1164/rccm.202408-1655oc
- Citations
- 2
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- National Natural Science Foundation of China